Table 1 Patient demographics and baseline disease characteristics
Cohort 1 (12 to < 18 years) N = 8 | Cohort 2 (6 to < 12 years) N = 9 | Cohort 3 (2 to < 6 years) N = 9 | All patients (2 to < 18 years) N = 26 | |
|---|---|---|---|---|
Age at enrollment, years | ||||
Median (Q1–Q3) | 14.0 (12.0–16.0) | 10.0 (8.0–11.0) | 4.0 (4.0–5.0) | 9.5 (5.0–12.0) |
Gender, n (%) | ||||
Female | 5 (62.5) | 5 (55.6) | 7 (77.8) | 17 (65.4) |
Body mass index,a kg/m2 | ||||
Median (Q1–Q3) | 19.9 (17.1–21.9) | 16.6 (15.9–20.4) | 14.4 (14.3–16.2) | 16.5 (15.0–20.2) |
Height, cm | ||||
Median (Q1–Q3) | 168.8 (157.5–171.7) | 135.0 (129.7–141.7) | 109.7 (99.6–111.6) | 134.5 (111.4–155.0) |
Disease duration (years) | ||||
Median (Q1–Q3) | 1.2 (0.7–1.7) | 0.5 (0.3–2.0) | 2.8 (1.3–3.1) | 1.4 (0.6–2.8) |
JIA categories | ||||
Polyarthritis (RF-)b, n (%) | 6 (75.0) | 7 (77.8) | 9 (100.0) | 22 (84.6) |
Psoriatic arthritis, n (%) | 1 (12.5) | 1 (11.1) | 0 | 2 (7.7) |
Extended oligoarthritis, n (%) | 1 (12.5) | 1 (11.1) | 0 | 2 (7.7) |
Disease characteristics | ||||
Physician’s global assessment of overall disease activityc | ||||
Median (Q1–Q3) | 7.5 (6.3–8.0) | 8.0 (6.0–8.5) | 6.5 (6.0–7.5) | 7.3 (6.0–8.0) |
Number of joints with active arthritisc,d | ||||
Median (Q1–Q3) | 15.5 (13.0–18.0) | 17.0 (10.0–21.0) | 10.0 (8.0–20.0) | 14.0 (8.0–21.0) |
Number of joints with limitation of motionc | ||||
Median (Q1–Q3) | 14.0 (8.5–16.5) | 9.0 (8.0–15.0) | 8.0 (6.0–20.0) | 10.0 (7.0–17.0) |
CHAQ functional ability | ||||
Median (Q1–Q3) | NA | 1.0 (0.4–1.6) | 0.9 (0.6–1.5) | 0.9 (0.4–1.6) |
C-reactive protein, mg/Le | ||||
Median (Q1–Q3) | 0.3 (0.2–0.5) | 0.6 (0.4–2.3) | 2.2 (0.3–13.9) | 0.5 (0.2–5.2) |
Concomitant drugs | ||||
Methotrexate use, mg/week | ||||
n (%) | 1 (12.5%) | 0 | 8 (88.9%) | 9 (34.6%) |
Median dose (Q1–Q3) | 25.0 (25.0–25.0) | 10.0 (9.4–11.9) | 10.0 (10.0–13.7) | |
Prednisone use, mg/day | ||||
n (%) | 2 (22.2%) | 2 (7.7%) | ||
Median dose (Q1–Q3) | 0 | 0 | 3.5 (2.0–5.0) | 3.5 (2.0–5.0) |